drugset
drugset / Trial / NCT01669798

BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer

NCT01669798 ↗

Phase 2 Completed 32 enrolled AA Secord Boehringer Ingelheim · collab
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to see if BIBF 1120 can increase the number of women with bevacizumab resistant, persistent, or recurrent epithelial ovarian cancer who do not progress for at least six months.

Timeline

Start
2013-02
Primary completion
2017-09-10
Completion
2018-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Nintedanib Small molecule 200 mg Oral

Indications

fallopian tube cancer ovarian cancer peritoneum cancer